Meditech begins second stage of Phase II
Monday, 06 December, 2004
Meditech Research (ASX:MTR) has commenced the second stage of its Phase II trial of HyCAMP, its proprietary formulation of chemotherapeutic drug irinotecan in combination with hyaluronic acid.
The trial will examine the safety and efficacy of HyCAMP and compare it to irinotecan alone in 86 patients previously treated with 5-fluorouracil. The trial is expected to be completed in mid-2006.
In an earlier uncontrolled study testing HyCAMP in twelve patients, the treatment showed similar efficacy with improved safety.
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
Shingles vaccine may reduce risk of heart attack and stroke
Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...
